Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.33 |
| ▸ | GABRD | O14764 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.33 |
| ▸ | GABRE | P78334 | 3/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hymexazol SCHEMBL9057951 | 0.77 | GABRP (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hymexazol SCHEMBL8820050 | 0.76 | GABRA1 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hymexazol SCHEMBL20728 | 0.76 | — | — | |
| Hymexazol SCHEMBL2106501 | 0.74 | — | — | |
| SCHEMBL19127368 | 0.72 | ENPP2 (0.33) | — | |
| SCHEMBL73933 | 0.72 | — | — | |
| Hymexazol SCHEMBL5466985 | 0.70 | ALDH1A1 (0.34) | KDM4EMEN1KMT2ATSHR | |
| Potassium SCHEMBL29550261 | 0.70 | — | — | |
| SCHEMBL2106503 | 0.70 | — | — | |
| Hydroxyamine SCHEMBL6622692 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| EP-3655426-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | Novo Nordisk A/S (DK) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019016300-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-01-24 | — | — | WO | disclosed |
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| EP-3402811-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | Novo Nordisk A/S (DK) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017121850-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GABRP 1880/4885GABRD 2112/4885GABRA1 1238/4885 |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | EGFR, VEGFA, ERBB2 | GABRP 1948/4885GABRD 2710/4885GABRA1 1412/4885 |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | EGFR, LDLR, FFAR2 | GABRP 1880/4885GABRD 2112/4885GABRA1 1238/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GABRP 1880/4885GABRD 2112/4885GABRA1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.